IL12B and inflammatory bowel disease: This list of proteins includes IL12B, the target protein for an existing drug Ustekinumab, which is currently under Phase 3 and 4 trials for IBD treatment (drug trial information available via Open Targets https://www.targetvalidation.org/evidence/ENSG00000113302/EFO_0000540?view=sec:known_drug).